3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
5
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Multiple Myeloma
41
Recurrence
14
Prostatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Vomiting
1
Vascular Diseases
1
Paraproteinemias
1
Neoplasms
1
Neoplasm Metastasis
1
Nausea
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Plasma Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Hemostatic Disorders
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Blood Coagulation Disorders
1
Interventions
Prednisone
103
enzalutamide
76
Docetaxel
72
Abiraterone Acetate
68
Leuprolide
47
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
45
abiraterone
39
apalutamide
29
Prednisolone
27
bicalutamide
26
Zoledronic Acid
24
radium Ra 223 dichloride
22
pembrolizumab
22
darolutamide
22
Goserelin
22
Triptorelin Pamoate
17
cabazitaxel
16
Androgen Antagonists
15
sipuleucel-T
13
luprolide acetate gel depot
12
Injections
12
Dexamethasone
12
olaparib
11
gallium 68 PSMA-11
10
Mitoxantrone
10
Pluvicto
9
Ipilimumab
9
Dutasteride
9
Cyclophosphamide
9
relugolix
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms
×
Calcium Dobesilate
×
Clear all
NCT06104449
2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts